[{"from": "human", "value": "Could you provide a description of this molecule? [C][C@@H1][C@H1][Branch2][Branch1][=Branch1][C][N][Ring1][Ring2][C][=C][C][=N][C][=Branch1][P][=C][C][Ring1][=Branch1][=C][Branch1][Branch1][C][=C][Ring1][#Branch2][C][Branch1][C][C][C][N][C][=N][C][=Branch1][=Branch1][=N][C][=C][Ring1][=Branch1][N][C][C][C@H1][Branch1][Branch2][C@H1][Branch1][Ring2][C][Ring1][=Branch1][F][O][C][C][S][=Branch1][C][=O][=Branch1][C][=O][C]"}, {"from": "gpt", "value": "The molecule is a fourth-generation, orally bioavailable, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor BLU-945 targets, binds to and inhibits the activity of EGFR with C797S triple mutations including ex19del/T790M/C797S and L858R/T790M/C797S, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. BLU-945 inhibits mutated forms of EGFR with C797S mutation, which prevents covalent bond formation with third-generation EGFR inhibitors leading to drug resistance. BLU-945 may have enhanced anti-tumor effects in tumors with C797S-mediated resistance when compared to other EGFR tyrosine kinase inhibitors."}]